These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 19292014)

  • 41. GUSTO V: should it affect clinical practice? Global Use of Strategies to Open Occluded Coronary Arteries.
    Orford JL; Berger PB
    Cleve Clin J Med; 2002 Jul; 69(7):520-2. PubMed ID: 12109634
    [No Abstract]   [Full Text] [Related]  

  • 42. Facilitated PCI for ST segment elevation myocardial infarction.
    Young JJ
    J Invasive Cardiol; 2004 Sep; Suppl():4-9. PubMed ID: 23573663
    [No Abstract]   [Full Text] [Related]  

  • 43. Too much, too little, or none at all: dealing with substandard and fake drugs.
    Wan Po AL
    Lancet; 2001 Jun; 357(9272):1904. PubMed ID: 11425409
    [No Abstract]   [Full Text] [Related]  

  • 44. [The AIDA STEMI study].
    Prati F; Limbruno U
    G Ital Cardiol (Rome); 2013 Oct; 14(10):631-5. PubMed ID: 24121885
    [No Abstract]   [Full Text] [Related]  

  • 45. [Optimal thrombolysis].
    Nordt TK; Bode C
    Z Kardiol; 2001 Aug; 90(8):591-5. PubMed ID: 11565215
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Update on management of acute myocardial infarction: facilitated percutaneous coronary intervention.
    Futterman LG; Lemberg L
    Am J Crit Care; 2000 Jan; 9(1):70-6. PubMed ID: 10631393
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Benefical effects of reteplase in combination with abciximab: platelet/leukocyte interactions and coagulation system.
    Szabo S; Walter T; Etzel D; Ehlers R; Kazmaier S; Beyer ME; Hoffmeister HM
    Int J Clin Pharmacol Res; 2003; 23(2-3):37-40. PubMed ID: 15018016
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The CAPTIM study.
    Dudek D; Kaluza GL; Zmudka K; Tracz W; Dubiel JS;
    Lancet; 2003 Feb; 361(9358):700-1; author reply 701. PubMed ID: 12606193
    [No Abstract]   [Full Text] [Related]  

  • 49. Pharmacological facilitation of coronary intervention in ST-segment elevation myocardial infarction: time is of the essence.
    Gersh BJ; Stone GW
    JACC Cardiovasc Interv; 2010 Dec; 3(12):1292-4. PubMed ID: 21232724
    [No Abstract]   [Full Text] [Related]  

  • 50. [Workshop II--Clinical and therapeutic pathways].
    Ital Heart J; 2005 Nov; 6 Suppl 6():12S-26S. PubMed ID: 16491742
    [No Abstract]   [Full Text] [Related]  

  • 51. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators.
    Schömig A; Kastrati A; Dirschinger J; Mehilli J; Schricke U; Pache J; Martinoff S; Neumann FJ; Schwaiger M
    N Engl J Med; 2000 Aug; 343(6):385-91. PubMed ID: 10933737
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction.
    Kaul P; Armstrong PW; Cowper PA; Eisenstein EL; Granger CB; Van de Werf F; Mark DB
    Am Heart J; 2005 Apr; 149(4):637-44. PubMed ID: 15990746
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
    Brener SJ; Moliterno DJ; Lincoff AM; Steinhubl SR; Wolski KE; Topol EJ
    Circulation; 2004 Aug; 110(8):994-8. PubMed ID: 15302778
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [ASSENT III and GUSTO V: is it the end of combination therapy with GPIIb/IIIa blockers and thrombolytics in myocardial infarction?].
    Vahanian A
    Ann Cardiol Angeiol (Paris); 2002 Jan; 51(1):6-7. PubMed ID: 12471654
    [No Abstract]   [Full Text] [Related]  

  • 55. Bivalirudin in acute myocardial infarction: "primum non nocere": the eternal dilemma: balancing risks and benefits in high-risk patients.
    Alfonso F; Paulo M
    JACC Cardiovasc Interv; 2010 Aug; 3(8):803-5. PubMed ID: 20723850
    [No Abstract]   [Full Text] [Related]  

  • 56. Combined glycoprotein IIb/IIIa receptor inhibition and low-dose fibrinolysis for peripheral arterial thrombosis.
    Rocha-Singh KJ; Trokey J
    Catheter Cardiovasc Interv; 2002 Apr; 55(4):457-60. PubMed ID: 11948891
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial.
    Mehilli J; Kastrati A; Schulz S; Früngel S; Nekolla SG; Moshage W; Dotzer F; Huber K; Pache J; Dirschinger J; Seyfarth M; Martinoff S; Schwaiger M; Schömig A;
    Circulation; 2009 Apr; 119(14):1933-40. PubMed ID: 19332467
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The benefits of platelet glycoprotein IIb/IIIa receptor inhibition during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: drug-specific or class effect?
    Brener SJ
    J Am Coll Cardiol; 2009 May; 53(18):1674-6. PubMed ID: 19406343
    [No Abstract]   [Full Text] [Related]  

  • 59. [Platelet membrane glycoproteins as site of pharmacological intervention in the treatment of coronary disease].
    Neumann FJ; Gawaz M; Schömig A
    Dtsch Med Wochenschr; 1997 Oct; 122(40):1224-30. PubMed ID: 9378047
    [No Abstract]   [Full Text] [Related]  

  • 60. Platelet reactivity and percutaneous coronary intervention: another clue in the quest for the Holy Grail of tailored antithrombotic therapy?
    Di Sciascio G; Mangiacapra F
    J Am Coll Cardiol; 2012 Jul; 60(5):378-80. PubMed ID: 22682552
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.